Salusin-α attenuates inflammatory responses in vascular endothelial cells


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Atherosclerosis accounts for numerous cardiovascular diseases, and cytokines have a critical role in acceleration or suppression of disease. Salusin-α presents a new class of bioactive peptides that can have anti-atherogenic properties. Therefore, the effects of salusin-α on the expression of some pro- and anti-inflammatory cytokines and on TNF-α-induced inflammatory responses in human umbilical vein endothelial cells (HUVECs) were examined. The involvement of the NF-κB pathway in effects of salusin-α in HUVECs was checked using Bay 11-7082 as an NF-κB inhibitor. The mRNA expression of pro-inflammatory cytokines including IL-6, IL-8, and IL-18 and anti-inflammatory cytokine IL-1Ra was assessed by real-time PCR. The protein levels of cytokines were measured by the ELISA method. Salusin-α suppressed both mRNA and protein expression of pro-inflammatory cytokines and induced mRNA and protein expression of IL-1Ra in HUVECs. Salusin-α suppressed TNF-α-induced inflammatory responses in HUVECs. The down-regulatory or up-regulatory effects of salusin-α on expression of cytokines could not be influenced by Bay 11-7082 pretreatment. Our findings indicate anti-inflammatory effects of salusin-α and suggest a novel peptide-based therapeutic strategy for atherosclerosis.

About the authors

Maryam Esfahani

Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Sciences Research Center

Email: najafi2535@gmail.com
Iran, Islamic Republic of, Isfahan

Masoud Saidijam

Research Center for Molecular Medicine

Email: najafi2535@gmail.com
Iran, Islamic Republic of, Hamadan

Mohammad Taghi Goodarzi

Research Center for Molecular Medicine; Hamadan University of Medical Sciences, School of Medicine

Email: najafi2535@gmail.com
Iran, Islamic Republic of, Hamadan; Hamadan

Ahmad Movahedian

Isfahan University of Medical Sciences, School of Pharmacy and Pharmaceutical Sciences and Isfahan Pharmaceutical Sciences Research Center

Author for correspondence.
Email: Movahedian@pharm.mui.ac.ir
Iran, Islamic Republic of, Isfahan

Rezvan Najafi

Research Center for Molecular Medicine

Author for correspondence.
Email: najafi2535@gmail.com
Iran, Islamic Republic of, Hamadan


Copyright (c) 2017 Pleiades Publishing, Ltd.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies